List of figures, tables and boxes
About the authors
Woodhead Publishing Series in Biomaterials
Chapter 1: Overview of tissue engineering/regenerative medicine
1.4 Therapeutic product delivery
Chapter 2: Cells
2.2 Mechanism of action of cell-based therapeutics
2.3 Other stem cell-based therapeutics currently under development
2.4 Development of genome modification technologies: gene-based cell therapies
2.5 Committed cell types: ideal candidates for TE/RM product development
2.6 Summary: key features favoring commercial development of cellular ABIs
Chapter 3: Biomaterials for TE/RM products
3.2 The ECM: comparator for biomaterials
3.3 Decell/recell: the ultimate biomaterial platform?
3.4 Selection of biomaterials for tissue engineering: illustrative example – kidney
3.5 Biomaterials candidates for renal tissue engineering
3.6 Selection of biomaterials for tubular organs: bladder, esophagus and small intestine
Chapter 4: Neo-Bladder: a foundational technology platform for tubular organ regeneration
4.1 The need for urinary neo-organs
4.2 TE/RM methodologies for bladder replacement and augmentation
4.3 Demonstration of Neo-Bladder formation in large animals
4.4 Can neo-bladder constructs be made from cells sourced from diseased patients?
4.5 Neo-bladder replacement in human pediatric patients – first clinical trials of a neo-organ
4.6 Making the product: cell sourcing
4.7 Definition of the cell source used for seeding neo-bladders: adipose
4.8 Other approaches to tissue engineering neo-bladders
4.9 Key results from development of the Neo-Bl
Developments in tissue engineered and regenerative medicine products summarizes recent developments in tissue engineering and regenerative medicine with an emphasis on commercialization and product development. Features of current cell therapy and tissue engineered products which have facilitated successful commercialization are emphasized and roadblocks to successful product development are also highlighted. Preclinical and clinical testing of tissue engineered and regenerative medicine products, regulatory, quality control, manufacturing issues, as well as generating and securing intellectual property and freedom to operate considerations are presented. This book represents a complete 'how-to' manual for the development of tissue engineered and regenerative medicine products from conceptualization to clinical trial to manufacturing.
- Addresses practical considerations for the field of tissue engineering and regenerative medicine from the perspective of the biotechnology industry
- Written as a manual for tissue engineering and regenerative medicine product development applicable to the US and EU
- Illustrates pathway integration of science and business required for successful product development
Industry professionals and entrepreneurial academics contemplating new start-ups focused on tissue engineering and regenerative medicine; Entrepreneurially minded students interested in biotechnology
- No. of pages:
- © Woodhead Publishing 2012
- 19th April 2012
- Woodhead Publishing
- eBook ISBN:
- Hardcover ISBN:
Dr Joydeep Basu is Senior Scientist, Bioprocess R&D, Tengion Inc., in Winston-Salem, North Carolina, USA. He has over 10 years' experience in the creation, research and development of cell therapy, gene therapy, regenerative medicine and tissue engineered products within entrepreneurial biotechnology companies including Athersys Inc (Cleveland, USA) and Tengion Inc (North Carolina, USA). Dr. Basu is a recognized global authority on the development of non-integrative gene therapy products and has published and presented broadly within the field of regenerative medicine/tissue engineering. He is currently focused on driving development of Tengion's tubular organ regeneration platform technology for applications beyond regeneration of bladder.
Dr John W. Ludlow is Senior Director, Process Research and Assay Development, Tengion Inc., in Winston-Salem, North Carolina, USA. With experiences as Director of the Cell Therapy Program at Incara Pharmaceuticals, and Senior Director of the Cell Therapy Program at Vesta Therapeutics (North Carolina, USA), he has achieved demonstrable successes in managing and directing therapeutic area-specific research and regenerative medicine and tissue engineering product development. Responsibilities have included bringing new products into bioprocessing research and development, taking new products to demonstration in animal models, GLP and non-GLP production, and initiation of human clinical trial sites. Dr. Ludlow has previous held faculty memberships at the Rochester Institute of Technology and the University of Rochester Cancer Center, with authorship on over 80 scientific publications.
Tengion Inc, USA